82 related articles for article (PubMed ID: 22960271)
1. Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma.
Zhang X; Wang W; Mize GJ; Takayama TK; True LD; Vessella RL
Exp Mol Pathol; 2013 Feb; 94(1):91-7. PubMed ID: 22960271
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
3. Protease-activated receptor 2 enhances renal cell carcinoma cell invasion and migration via PI3K/AKT signaling pathway.
Sun Z; Cao B; Wu J
Exp Mol Pathol; 2015 Jun; 98(3):382-9. PubMed ID: 25773677
[TBL] [Abstract][Full Text] [Related]
4. Proteinase-activated receptor-1 and -2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain.
Wang Y; Luo W; Reiser G
Biochem J; 2007 Jan; 401(1):65-78. PubMed ID: 16942465
[TBL] [Abstract][Full Text] [Related]
5. Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1.
Wang Y; Luo W; Stricker R; Reiser G
J Neurochem; 2006 Aug; 98(4):1046-60. PubMed ID: 16749907
[TBL] [Abstract][Full Text] [Related]
6. PAR-2 activation regulates IL-8 and GRO-alpha synthesis by NF-kappaB, but not RANTES, IL-6, eotaxin or TARC expression in nasal epithelium.
Rudack C; Steinhoff M; Mooren F; Buddenkotte J; Becker K; von Eiff C; Sachse F
Clin Exp Allergy; 2007 Jul; 37(7):1009-22. PubMed ID: 17581194
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract][Full Text] [Related]
8. PAR-2 activation in intestinal epithelial cells potentiates interleukin-1beta-induced chemokine secretion via MAP kinase signaling pathways.
Fyfe M; Bergström M; Aspengren S; Peterson A
Cytokine; 2005 Sep; 31(5):358-67. PubMed ID: 16095910
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
[TBL] [Abstract][Full Text] [Related]
11. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis.
Seitz I; Hess S; Schulz H; Eckl R; Busch G; Montens HP; Brandl R; Seidl S; Schömig A; Ott I
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):769-75. PubMed ID: 17255532
[TBL] [Abstract][Full Text] [Related]
12. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma.
Nomura T; Huang WC; Seo S; Zhau HE; Mimata H; Chung LW
J Urol; 2007 Jul; 178(1):292-300. PubMed ID: 17499801
[TBL] [Abstract][Full Text] [Related]
13. Signal of proteinase-activated receptor-2 contributes to highly malignant potential of human pancreatic cancer by up-regulation of interleukin-8 release.
Ikeda O; Egami H; Ishiko T; Ishikawa S; Kamohara H; Hidaka H; Takahashi M; Ogawa M
Int J Oncol; 2006 Apr; 28(4):939-46. PubMed ID: 16525644
[TBL] [Abstract][Full Text] [Related]
14. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.
Veliceasa D; Ivanovic M; Hoepfner FT; Thumbikat P; Volpert OV; Smith ND
FEBS J; 2007 Dec; 274(24):6365-77. PubMed ID: 18021253
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Hemmerlein B; Galuschka L; Putzer N; Zischkau S; Heuser M
Histopathology; 2004 Dec; 45(6):603-11. PubMed ID: 15569051
[TBL] [Abstract][Full Text] [Related]
16. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
18. Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines.
Dutra-Oliveira A; Monteiro RQ; Mariano-Oliveira A
Biochem Biophys Res Commun; 2012 May; 421(2):221-7. PubMed ID: 22497886
[TBL] [Abstract][Full Text] [Related]
19. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.
Trevino JG; Summy JM; Gray MJ; Nilsson MB; Lesslie DP; Baker CH; Gallick GE
Cancer Res; 2005 Aug; 65(16):7214-22. PubMed ID: 16103072
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer K; Zelle-Rieser C; Perathoner A; Moser P; Hager M; Ramoner R; Gander H; Höltl L; Bartsch G; Greil R; Thurnher M
Clin Cancer Res; 2005 Apr; 11(7):2459-65. PubMed ID: 15814620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]